



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK’S SCIENTIFIC ADVISOR NAMED DEAN OF SCHULICH SCHOOL OF MEDICINE AND DENTISTRY

Vancouver, British Columbia – (January 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) and its team of scientific advisors would like to congratulate Dr. John Yoo for being named Dean of the Schulich School of Medicine & Dentistry on January 6th, 2020.

Dr. Yoo has an international reputation as a pioneering surgeon and an exemplary academic and clinical leader. He currently serves Western as Interim Chair/Chief of the Department of Paediatrics, as Fellowship Director for the Department of Otolaryngology – Head & Neck Surgery, and as a Professor of Otolaryngology and Oncology. Prior to these roles, Dr. Yoo served as Chair/Chief of the Department of Otolaryngology – Head & Neck Surgery for 10 years. As a surgeon, Dr. Yoo pioneered and popularized a technique for reconstructive facial surgery that has been adopted around the world. He has served as Co-Chair of the London Health Sciences Centre’s Facial Nerve Clinic since 2007. Today, in addition to his academic, leadership and clinical roles, Dr. Yoo serves as the Co-chair of Cancer Care Ontario Head and Neck Cancer Disease Site, is the President-elect of the Canadian Association of Head and Neck Surgical Oncology and is an executive board member with the Canadian Association of Otolaryngology and the Asia-Pacific Society of Thyroid Surgery, and he was the longest-serving Chair of the Canadian Chairs of Otolaryngology.

Dr. Yoo will step into his new role as Schulich Medicine & Dentistry’s next Dean on May 1, 2020.

“BioMark would like to take this opportunity to wish Dr. Yoo the very best in his new role. His vision, passion to inspire and guide individuals and institutions is exemplary. BioMark is fortunate to have been supported with his counsel in establishing a rigorous emphasis to focus on end point driven clinical research” says BioMark ‘s CEO and President Rashid Ahmed.

ABOUT WESTERN

Western University delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community.

ABOUT THE SCHULICH SCHOOL OF MEDICINE & DENTISTRY

The Schulich School of Medicine & Dentistry at Western University is one of Canada's preeminent medical and dental schools. Established in 1881, it was one of the founding schools of Western University and is known for being the birthplace of family medicine in Canada. For more than 130 years, the School has demonstrated a commitment to academic excellence and a passion for scientific discovery.

ABOUT LONDON HEALTH SCIENCES CENTRE

London Health Sciences Centre has been at the forefront of medicine in Canada for 145 years and offers the broadest range of specialized clinical services in Ontario. Building on the traditions of its founding hospitals to provide compassionate care in an academic teaching setting, London Health Sciences Centre is home to Children's Hospital, University Hospital, Victoria Hospital, the Kidney Care Centre, two family medical centres, and two research institutes – Children's Health Research Institute and Lawson Health Research Institute. As a leader in medical discovery and health research, London Health Sciences Centre has a history of over 70 international and national firsts and attracts top clinicians and researchers from around the world. As a regional referral centre, London Health Sciences Centre cares for the most medically complex patients including critically injured adults and children in southwestern Ontario and beyond. The hospital's nearly 15,000 staff, physicians, students and volunteers provide care for more than one million patient visits a year.

ABOUT BIOMARK DIAGNOSTICS INC.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <https://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: info@biomarkdiagnostics.com

Company website: www.biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.